REG - PureTech Health PLC - Half Yearly Report <Origin Href="QuoteRef">ANTO.L</Origin> <Origin Href="QuoteRef">PRTC.L</Origin> - Part 3

AntofagastaAnnouncement

25/08/2015 07:00

- Part 3: For the preceding part double click  ID:nRSY9495Wb 

$3.84 million to further develop its lead program, KarXT, a potentially
innovative therapy for the treatment of schizophrenia. 
 
Statement of Directors' Responsibilities 
 
The Directors confirm to the best of their knowledge that: 
 
a.)  the condensed set of financial statements have been prepared in
accordance with IAS 34 as adopted by the European Union; and 
 
b.)  the interim management report includes a fair review of the information
required by the FCA's Disclosure and Transparency Rules (4.2.7 R and 4.2.8 R) 
 
By order of the Board 
 
 Joichi ItoChairman  Daphne ZoharChief Executive Officer  
 
 
21 August 2015 
 
Further information for shareholders: 
 
Company Registration Number 
 
9582467 
 
Registered Office 
 
5th Floor 
 
6 St Andrew Street 
 
London EC4A 3AE 
 
United Kingdom 
 
Website 
 
http://www.puretechhealth.com 
 
Board of Directors 
 
Mr. Joichi Ito (Non-Executive Chairman) 
 
Ms. Daphne Zohar (Chief Executive Officer) 
 
Dame Marjorie Scardino (Senior Independent Director) 
 
Dr. Bennett Shapiro (Non-Executive Director) 
 
Dr. Robert Langer (Non-Executive Director) 
 
Dr. Raju Kucherlapati (Independent Non-Executive Director) 
 
Dr. John LaMattina (Independent Non-Executive Director) 
 
Mr. Christopher Viehbacher (Independent Non-Executive Director) 
 
Mr. Stephen Muniz (Executive Vice President, Legal, Finance and Operations) 
 
Company Secretary 
 
Mr. Stephen Muniz 
 
This information is provided by RNS
The company news service from the London Stock Exchange